Image Description (Desvenlafaxine Tablets Figure 1)
Desvenlafaxine Tablet, Extended Release
Product Images NDC 50090-7190
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-7190). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Description (Desvenlafaxine Tablets Figure 2)
This text provides information on the changes in Ketoconazole Cmax when combined with CYP3A4 inhibitors, specifically showing the geometric mean ratio and confidence intervals. It indicates that the Cmax levels of Ketoconazole increase compared to the reference values when CYP3A4 Inhibitors are present.*
Image Description (Desvenlafaxine Tablets Figure 3)
Image Description (Desvenlafaxine Tablets Figure 4)
The text provides an estimated proportion of patients with a relapse over time, comparing Desverla 50mg to Placebo. It shows that after 40 days from randomization, there is a difference in relapse rates between the two groups.*
Image Description (Desvenlafaxine Tablets Figure 5)
Estimated proportion of patients with relapse over time (days from randomization), comparing Desvenlafaxine and Placebo treatments. Data is presented in a graphical format showing the relapse rates at different time intervals.*
Image Description (Desvenlafaxine Tablets Structure)
Label Image (Lbl500907190)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
